COVALON TECH LTD. (ISIN: CA22282D1042)WKN: A2H7RH
Seite 1 von 1 Neuester Beitrag: 27.02.19 20:27 | ||||
| Eröffnet am: | 01.01.18 15:03 | von: Tamakoschy | Anzahl Beiträge: | 11 |
| Neuester Beitrag: | 27.02.19 20:27 | von: Tamakoschy | Leser gesamt: | 2.973 |
| Forum: | Börse | Leser heute: | 1 | |
| Bewertet mit: |  | |||
What We Do
Covalon uses science and technology to help solve major medical challenges associated with prevention, detection and management of areas such as infection, tissue repair, medical device biocompatibility, and condition management.
Together, our technology platforms, wound care products, and consulting services deliver a suite of cost-effective solutions to help our customers achieve product differentiation through improved patient outcomes.
http://www.covalon.com/about-us/
Press Releases
Covalon Announces Major Sales Breakthrough – Wins Contracts with an Estimated Value of $100 Million Over a Three-Year Period
Conference call scheduled for Tuesday May 8th at 9am EDT to discuss the impact of this major transformative event
MISSISSAUGA, Ontario--(BUSINESS WIRE)--May 7, 2018-- Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV; OTCQX: CVALF), an advanced medical technologies company, has been informed that it has won a series of competitive contracts in the Middle East with an estimated sales value of $100 million over a three-year period.
http://ir.covalon.com/...183092&p=irol-newsArticle&ID=2347283
Covalon targets attractive markets with its products. There is massive room for growth going forward.
International expansion will be a major growth driver over the next couple of years.
Shares are inexpensive, and there is a lot of room for share price gains.
Weiter hier: https://seekingalpha.com/article/...-price-gains-covalon-coming-years
Brian Pedlar, Chief Executive Officer of Covalon, said, “I am very excited about this acquisition – AquaGuard’s experienced sales team and specialized product line are a perfect synergistic fit for Covalon’s business. AquaGuard’s talented sales team has built strong relationships with clinicians and hospital staff throughout the United States that make decisions on the very same products Covalon makes – vascular access dressings, surgical site management products, and advanced wound care dressings.”
Gerry Arambula, President of AquaGuard, stated, “The AquaGuard sales and operations teams are very excited about joining forces with Covalon. Our AquaGuard team has built a profitable and growing business that is well-positioned to represent and sell many of Covalon’s infection management products, such as IV Clear, immediately into our customer base. We are looking forward to working with the Covalon team to transform Covalon’s business in the United States. Products will be made available through AquaGuard’s established distribution channels at key hospitals and group purchasing organizations across the United States, as well as through third-party distribution partners, including Amazon.”